Helicobacter pylori Infection Does Not Impact on Lung Transplant Outcome.
Adult
Female
Helicobacter Infections
/ diagnosis
Helicobacter pylori
/ pathogenicity
Humans
Italy
/ epidemiology
Lung Diseases
/ diagnosis
Lung Transplantation
/ adverse effects
Male
Middle Aged
Patient Readmission
Postoperative Complications
/ epidemiology
Prevalence
Risk Factors
Time Factors
Treatment Outcome
Epidemiology
Helicobacter pylori
Lung transplantation
Journal
Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
02
07
2018
accepted:
07
11
2018
pubmed:
21
11
2018
medline:
16
1
2020
entrez:
21
11
2018
Statut:
ppublish
Résumé
Helicobacter pylori (HP) is a spiral, gram-negative, microaerophilic bacterium that colonises the human gastric mucosa and is associated with gastrointestinal and extragastrointestinal disorders. Since no data are yet available on HP infection in lung transplant patients, we evaluated the prevalence and impact of HP infection in a population of such patients. Sixty-seven lung transplant patients were enrolled in the study (35 females and 32 males, age 48.4 ± 13.3 years), 54 underwent bilateral and 13 single lung transplant. Serum antibodies against HP and CagA were assayed in all subjects. The prevalence of HP infection in lung transplant patients was similar to that in the general population (49.25% vs. 51.4%), whereas HP-positive patients showed lower CagA positivity (9% vs. 50.2%, p < 0.0001). There was a higher prevalence of HP infection in patients who underwent lung transplant because of pulmonary fibrosis (p = 0.049), and a lower prevalence in COPD patients (p = 0.011). No correlation was found between HP infection in lung transplant patients and graft outcome. No differences in primary graft dysfunction, acute rejection or bronchiolitis obliterans syndrome-free survival were found. However, more patients who required three or more post-transplant re-hospitalisations were observed among HP-positive patients. The prevalence of HP infection in lung transplant patients was comparable to that of the general population and to that reported in heart and kidney transplant recipients. It did not seem to impact short-, mid- or long-term lung allograft outcome. H. pylori infection did not prove to be clinically relevant in lung transplant patients.
Sections du résumé
BACKGROUND
Helicobacter pylori (HP) is a spiral, gram-negative, microaerophilic bacterium that colonises the human gastric mucosa and is associated with gastrointestinal and extragastrointestinal disorders. Since no data are yet available on HP infection in lung transplant patients, we evaluated the prevalence and impact of HP infection in a population of such patients.
METHODS
Sixty-seven lung transplant patients were enrolled in the study (35 females and 32 males, age 48.4 ± 13.3 years), 54 underwent bilateral and 13 single lung transplant. Serum antibodies against HP and CagA were assayed in all subjects.
RESULTS
The prevalence of HP infection in lung transplant patients was similar to that in the general population (49.25% vs. 51.4%), whereas HP-positive patients showed lower CagA positivity (9% vs. 50.2%, p < 0.0001). There was a higher prevalence of HP infection in patients who underwent lung transplant because of pulmonary fibrosis (p = 0.049), and a lower prevalence in COPD patients (p = 0.011). No correlation was found between HP infection in lung transplant patients and graft outcome. No differences in primary graft dysfunction, acute rejection or bronchiolitis obliterans syndrome-free survival were found. However, more patients who required three or more post-transplant re-hospitalisations were observed among HP-positive patients.
CONCLUSIONS
The prevalence of HP infection in lung transplant patients was comparable to that of the general population and to that reported in heart and kidney transplant recipients. It did not seem to impact short-, mid- or long-term lung allograft outcome. H. pylori infection did not prove to be clinically relevant in lung transplant patients.
Identifiants
pubmed: 30456701
doi: 10.1007/s00408-018-0178-7
pii: 10.1007/s00408-018-0178-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-99Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Helicobacter. 2017 Feb;22(1):
pubmed: 27411077
Transplantation. 2003 Aug 27;76(4):702-4
pubmed: 12973113
Am J Med. 2018 May;131(5):473-479
pubmed: 29353050
Helicobacter. 2012 Sep;17 Suppl 1:1-8
pubmed: 22958148
J Heart Lung Transplant. 1997 Jun;16(6):596-9
pubmed: 9229288
Respiration. 2016;91(1):3-8
pubmed: 26645213
J Biol Regul Homeost Agents. 2017 Jul 13;31(2 Suppl. 2):57-77
pubmed: 28702966
Panminerva Med. 2016 Dec;58(4):304-317
pubmed: 27716738
Helicobacter. 2017 Sep;22 Suppl 1:
pubmed: 28891127
World J Gastroenterol. 2014 Jan 21;20(3):714-23
pubmed: 24574745
Transplant Proc. 2016 Jan-Feb;48(1):92-5
pubmed: 26915849
Biochem Biophys Res Commun. 2015 May 8;460(3):721-726
pubmed: 25817795
Ann Allergy Asthma Immunol. 2017 Aug;119(2):137-145.e2
pubmed: 28634020
Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):69-74
pubmed: 25063740
Nephrol Dial Transplant. 2001 Oct;16(10):2053-7
pubmed: 11572896
Eur Respir J. 2014 Feb;43(2):635-8
pubmed: 24114963
Br J Haematol. 2015 Feb;168(3):421-8
pubmed: 25257094
J Am Geriatr Soc. 2015 Aug;63(8):1540-5
pubmed: 26289683
Jundishapur J Microbiol. 2014 Dec 07;8(1):e14551
pubmed: 25789128
Infect Immun. 2010 Feb;78(2):845-53
pubmed: 19917709
Thorax. 2015 Oct;70(10):923-9
pubmed: 26024688
Eur Heart J Acute Cardiovasc Care. 2017 Sep;6(6):535-544
pubmed: 26798071
Gastroenterology. 2016 May;150(5):1113-1124.e5
pubmed: 26836587